Cargando…
Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer
BACKGROUND: Several scan parameters for PET imaging with (18)F-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide administration on lesion visualization. Forty-four patients were randomly assi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040121/ https://www.ncbi.nlm.nih.gov/pubmed/32095919 http://dx.doi.org/10.1186/s13550-020-0593-7 |
_version_ | 1783500923852554240 |
---|---|
author | Piron, Sarah De Man, Kathia Schelfhout, Vanessa Van Laeken, Nick Kersemans, Ken Achten, Eric De Vos, Filip Ost, Piet |
author_facet | Piron, Sarah De Man, Kathia Schelfhout, Vanessa Van Laeken, Nick Kersemans, Ken Achten, Eric De Vos, Filip Ost, Piet |
author_sort | Piron, Sarah |
collection | PubMed |
description | BACKGROUND: Several scan parameters for PET imaging with (18)F-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide administration on lesion visualization. Forty-four patients were randomly assigned to a dosage group (2.0 ± 0.2 or 4.0 ± 0.4 MBq/kg (18)F-PSMA-11). All patients received a full-body PET/CT 1 h and 3 h after radiotracer injection with a scan duration of 3 min/bed position. For comparison of the scan duration, images were reconstructed for 1.5 and 3 min/bed position. Patients were intravenously administered 0.5 mg/kg furosemide with a maximum dose of 40 mg. To evaluate the furosemide effect, 22 additional patients were recruited and received one full-body PET/CT 1 h after administration of 2.0 ± 0.2 MBq/kg (18)F-PSMA-11 with a scan duration of 3 min/bed position. To this group, no furosemide was administered. Images were scored on image quality using a 7-point scale and each suspicious lesion was described. To assess interrater reliability, two nuclear physicians scored all scans independently and described all observed suspicious lesions. RESULTS: The 4 MBq/kg group received for all reconstructed images (60 min p.i., 1.5 and 3 min/bed position and 180 min p.i., 1.5 and 3 min/bed position) the highest median image quality score compared to the 2 MBq/kg group (p values < 0.01). When comparing all reconstructed images, the highest image quality score was given to images at 60 min p.i., 3 min/bed position for both dosage groups (score 5 and 6 for 2 and 4 MBq/kg, respectively). The addition of furosemide administration decreased the interference score with one point (p = 0.01106) and facilitated the evaluation of lesions in proximity to the ureters. The interrater reliability for the comparison of each lesion separately after more than 40 (18)F-PSMA-11 scan readings showed an increasing κ value from 0.78 (95% CI, 0.65–0.92) to 0.94 (95% CI, 0.87–1). CONCLUSION: Although the results indicate an administered activity of 4.0 ± 0.4 MBq/kg, preference will be given to 2.0 ± 0.2 MBq/kg due to the small difference in absolute score (max 1 point) and the ALARA principle. For evaluation of lesions in proximity to the ureters, the co-administration of a diuretic can be useful. The increase of the κ value from 0.78 to 0.94 suggests a learning curve in the interpretation of (18)F-PSMA-11 images. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03573011. Retrospectively registered 28 June 2018 |
format | Online Article Text |
id | pubmed-7040121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-70401212020-03-10 Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer Piron, Sarah De Man, Kathia Schelfhout, Vanessa Van Laeken, Nick Kersemans, Ken Achten, Eric De Vos, Filip Ost, Piet EJNMMI Res Original Research BACKGROUND: Several scan parameters for PET imaging with (18)F-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide administration on lesion visualization. Forty-four patients were randomly assigned to a dosage group (2.0 ± 0.2 or 4.0 ± 0.4 MBq/kg (18)F-PSMA-11). All patients received a full-body PET/CT 1 h and 3 h after radiotracer injection with a scan duration of 3 min/bed position. For comparison of the scan duration, images were reconstructed for 1.5 and 3 min/bed position. Patients were intravenously administered 0.5 mg/kg furosemide with a maximum dose of 40 mg. To evaluate the furosemide effect, 22 additional patients were recruited and received one full-body PET/CT 1 h after administration of 2.0 ± 0.2 MBq/kg (18)F-PSMA-11 with a scan duration of 3 min/bed position. To this group, no furosemide was administered. Images were scored on image quality using a 7-point scale and each suspicious lesion was described. To assess interrater reliability, two nuclear physicians scored all scans independently and described all observed suspicious lesions. RESULTS: The 4 MBq/kg group received for all reconstructed images (60 min p.i., 1.5 and 3 min/bed position and 180 min p.i., 1.5 and 3 min/bed position) the highest median image quality score compared to the 2 MBq/kg group (p values < 0.01). When comparing all reconstructed images, the highest image quality score was given to images at 60 min p.i., 3 min/bed position for both dosage groups (score 5 and 6 for 2 and 4 MBq/kg, respectively). The addition of furosemide administration decreased the interference score with one point (p = 0.01106) and facilitated the evaluation of lesions in proximity to the ureters. The interrater reliability for the comparison of each lesion separately after more than 40 (18)F-PSMA-11 scan readings showed an increasing κ value from 0.78 (95% CI, 0.65–0.92) to 0.94 (95% CI, 0.87–1). CONCLUSION: Although the results indicate an administered activity of 4.0 ± 0.4 MBq/kg, preference will be given to 2.0 ± 0.2 MBq/kg due to the small difference in absolute score (max 1 point) and the ALARA principle. For evaluation of lesions in proximity to the ureters, the co-administration of a diuretic can be useful. The increase of the κ value from 0.78 to 0.94 suggests a learning curve in the interpretation of (18)F-PSMA-11 images. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03573011. Retrospectively registered 28 June 2018 Springer Berlin Heidelberg 2020-02-24 /pmc/articles/PMC7040121/ /pubmed/32095919 http://dx.doi.org/10.1186/s13550-020-0593-7 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Piron, Sarah De Man, Kathia Schelfhout, Vanessa Van Laeken, Nick Kersemans, Ken Achten, Eric De Vos, Filip Ost, Piet Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer |
title | Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer |
title_full | Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer |
title_fullStr | Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer |
title_full_unstemmed | Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer |
title_short | Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer |
title_sort | optimization of pet protocol and interrater reliability of (18)f-psma-11 imaging of prostate cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040121/ https://www.ncbi.nlm.nih.gov/pubmed/32095919 http://dx.doi.org/10.1186/s13550-020-0593-7 |
work_keys_str_mv | AT pironsarah optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer AT demankathia optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer AT schelfhoutvanessa optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer AT vanlaekennick optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer AT kersemansken optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer AT achteneric optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer AT devosfilip optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer AT ostpiet optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer |